No Clinically Significant Changes in Pulmonary Function Following Stereotactic Body Radiation Therapy for Early- Stage Peripheral Non-small Cell Lung Cancer: an Analysis of RTOG 0236

Overview

Journal Int J Radiat Oncol Biol Phys

Specialties Oncology
Radiology

Date 2014 Mar 26

PMID 24661663

Citations 55

Authors

Sinisa Stanic

Rebecca Paulus

Robert D Timmerman

Jeff M Michalski

Robert B Barriger

Andrea Bezjak

Gregory M M Videtic

Jeffrey Bradley

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate pulmonary function test (PFT) results and arterial blood gas changes (complete PFT) following stereotactic body radiation therapy (SBRT) and to see whether baseline PFT correlates with lung toxicity and overall survival in medically inoperable patients receiving SBRT for early stage, peripheral, non-small cell lung cancer (NSCLC).

Methods And Materials: During the 2-year follow-up, PFT data were collected for patients with T1-T2N0M0 peripheral NSCLC who received effectively 18 Gy × 3 in a phase 2 North American multicenter study (Radiation Therapy Oncology Group [RTOG] protocol 0236). Pulmonary toxicity was graded by using the RTOG SBRT pulmonary toxicity scale. Paired Wilcoxon signed rank test, logistic regression model, and Kaplan-Meier method were used for statistical analysis.

Results: At 2 years, mean percentage predicted forced expiratory volume in the first second and diffusing capacity for carbon monoxide declines were 5.8% and 6.3%, respectively, with minimal changes in arterial blood gases and no significant decline in oxygen saturation. Baseline PFT was not predictive of any pulmonary toxicity following SBRT. Whole-lung V5 (the percentage of normal lung tissue receiving 5 Gy), V10, V20, and mean dose to the whole lung were almost identical between patients who developed pneumonitis and patients who were pneumonitis-free. Poor baseline PFT did not predict decreased overall survival. Patients with poor baseline PFT as the reason for medical inoperability had higher median and overall survival rates than patients with normal baseline PFT values but with cardiac morbidity.

Conclusions: Poor baseline PFT did not appear to predict pulmonary toxicity or decreased overall survival after SBRT in this medically inoperable population. Poor baseline PFT alone should not be used to exclude patients with early stage lung cancer from treatment with SBRT.

Citing Articles

Navigating restriction from interstitial lung disease (ILD) with stereotactic ablative radiotherapy (SABR) in early-stage non-small cell lung cancer: soaring beyond the current treatment paradigm.

Kassardjian A, Malhotra J, Lee P Transl Cancer Res. 2025; 14(1):11-15.

PMID: 39974416 PMC: 11833375. DOI: 10.21037/tcr-24-1813.

Enhancing stereotactic ablative boost radiotherapy dose prediction for bulky lung cancer: A multi-scale dilated network approach with scale-balanced structure loss.

Huang L, Gao X, Li Y, Lyu F, Gao Y, Bai Y J Appl Clin Med Phys. 2024; 26(1):e14546.

PMID: 39374302 PMC: 11712318. DOI: 10.1002/acm2.14546.

Lung Cancer and Interstitial Lung Diseases.

Drakopanagiotakis F, Krauss E, Michailidou I, Drosos V, Anevlavis S, Gunther A Cancers (Basel). 2024; 16(16).

PMID: 39199608 PMC: 11352559. DOI: 10.3390/cancers16162837.

Stereotactic body radiotherapy in lung cancer: a contemporary review.

Csiki E, Simon M, Papp J, Barabas M, Mikaczo J, Gal K Pathol Oncol Res. 2024; 30:1611709.

PMID: 38476352 PMC: 10928908. DOI: 10.3389/pore.2024.1611709.

The role of online MR-guided multi-fraction stereotactic ablative radiotherapy in lung tumours.

Hering S, Nieto A, Marschner S, Hofmaier J, Schmidt-Hegemann N, da Silva Mendes V Clin Transl Radiat Oncol. 2024; 45:100736.

PMID: 38433949 PMC: 10909605. DOI: 10.1016/j.ctro.2024.100736.

References

GRAHAM M, Purdy J, Emami B, Harms W, Bosch W, Lockett M . Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999; 45(2):323-9. DOI: 10.1016/s0360-3016(99)00183-2. View

Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I . Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009; 27(20):3290-6. DOI: 10.1200/JCO.2008.21.5681. View

Baumann P, Nyman J, Hoyer M, Gagliardi G, Lax I, Wennberg B . Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol. 2008; 88(3):359-67. DOI: 10.1016/j.radonc.2008.07.019. View

Henderson M, McGarry R, Yiannoutsos C, Fakiris A, Hoopes D, Williams M . Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008; 72(2):404-9. DOI: 10.1016/j.ijrobp.2007.12.051. View

Xiao Y, Papiez L, Paulus R, Timmerman R, Straube W, Bosch W . Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009; 73(4):1235-42. PMC: 2911132. DOI: 10.1016/j.ijrobp.2008.11.019. View

Timmerman R, Galvin J, Michalski J, Straube W, Ibbott G, Martin E . Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using Stereotactic Body Radiation Therapy in lung cancer. Acta Oncol. 2006; 45(7):779-86. DOI: 10.1080/02841860600902213. View

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J . Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010; 303(11):1070-6. PMC: 2907644. DOI: 10.1001/jama.2010.261. View

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T . Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63(5):1427-31. DOI: 10.1016/j.ijrobp.2005.05.034. View

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, Deluca J . Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006; 24(30):4833-9. DOI: 10.1200/JCO.2006.07.5937. View

10.

McGarry R, Papiez L, Williams M, Whitford T, Timmerman R . Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys. 2005; 63(4):1010-5. DOI: 10.1016/j.ijrobp.2005.03.073. View

11.

Gopal R, Starkschall G, Tucker S, Cox J, Liao Z, Hanus M . Effects of radiotherapy and chemotherapy on lung function in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 56(1):114-20. DOI: 10.1016/s0360-3016(03)00077-4. View

12.

Timmerman R, Papiez L, McGarry R, Likes L, DesRosiers C, Frost S . Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003; 124(5):1946-55. DOI: 10.1378/chest.124.5.1946. View

13.

Seppenwoolde Y, Lebesque J, De Jaeger K, Belderbos J, Boersma L, Schilstra C . Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 2003; 55(3):724-35. DOI: 10.1016/s0360-3016(02)03986-x. View

14.

Roger V, Weston S, Redfield M, Hellermann-Homan J, Killian J, Yawn B . Trends in heart failure incidence and survival in a community-based population. JAMA. 2004; 292(3):344-50. DOI: 10.1001/jama.292.3.344. View

15.

Yom S, Liao Z, Liu H, Tucker S, Hu C, Wei X . Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68(1):94-102. DOI: 10.1016/j.ijrobp.2006.12.031. View

16.

Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S . Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003; 56(1):126-35. DOI: 10.1016/s0360-3016(03)00095-6. View

17.

Yorke E, Jackson A, Rosenzweig K, Braban L, Leibel S, Ling C . Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys. 2005; 63(3):672-82. DOI: 10.1016/j.ijrobp.2005.03.026. View

18.

Trotti A, Colevas A, Setser A, Rusch V, Jaques D, Budach V . CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13(3):176-81. DOI: 10.1016/S1053-4296(03)00031-6. View

19.

Stephans K, Djemil T, Reddy C, Gajdos S, Kolar M, Machuzak M . Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol. 2009; 4(7):838-44. DOI: 10.1097/JTO.0b013e3181a99ff6. View